PTPN22 and ovarian carcinoma: In the present work, we showed that Ptpn22–/– effector OT-1 CTLs had remarkable ability to target and kill ID8 ovarian carcinomas cells expressing the very low-affinity V4 OVA variant both in vitro and in vivo.